Invention Grant
US08435994B2 Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists
有权
取代的[1,2,4]三唑并[4,3-α]喹喔啉作为腺苷A2a受体拮抗剂
![Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists](/docs/US/2013-05-07/US08435994B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists
- Patent Title (中): 取代的[1,2,4]三唑并[4,3-α]喹喔啉作为腺苷A2a受体拮抗剂
-
Application No.: US13510094Application Date: 2010-11-12
-
Publication No.: US08435994B2Publication Date: 2013-05-07
- Inventor: Joel M. Harris , Bernard R. Neustadt , Andrew W. Stamford
- Applicant: Joel M. Harris , Bernard R. Neustadt , Andrew W. Stamford
- Applicant Address: US NJ Rahway
- Assignee: Merck Sharp & Dohme Corp.
- Current Assignee: Merck Sharp & Dohme Corp.
- Current Assignee Address: US NJ Rahway
- Agent Gerard M. Devlin; H. Eric Fischer
- International Application: PCT/US2010/056432 WO 20101112
- International Announcement: WO2011/060207 WO 20110519
- Main IPC: A61K31/495
- IPC: A61K31/495
![Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists](/abs-image/US/2013/05/07/US08435994B2/abs.jpg.150x150.jpg)
Abstract:
The present invention relates to certain fused tricyclic heteroaryl rings compounds of the Formula (I) (also referred to herein as the “Fused Tricyclic Compounds”), wherein M, Q, U, W, X, Y, Z, R1, R2, and R3, and rings C and D are as herein described. The present invention also provides compositions comprising at least one Fused Tricyclic Compound, and use of such compounds in the treatment of central nervous system diseases or disorders such as Parkinson's disease.
Public/Granted literature
- US20120232086A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY Public/Granted day:2012-09-13
Information query
